Oct 22, 2025 6:30 AM Eastern Daylight Time Henry Schein to Participate in Upcoming Investor Conferences in November Share MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc., (Nasdaq: HSIC) the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conferences in November: Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be av ...

Core Insights - CYIOS Corporation announced the resignation of David Lewis, who returned 16,560 Series D Preferred Shares and canceled all salary and loan obligations, strengthening the company's balance sheet and simplifying its capital structure [1] - The company is completing PCAOB-audited financial statements for the past two years, with 2024 fully completed, enhancing transparency and compliance [2] - CYIOS is focusing on increasing working capital through strategic investments to pay down Noir Medical Supplies' debt obligations, expected to be completed by mid-2026 [2] - The company is engaging AI and SaaS advisors to develop CyioIQ, an AI-driven medical platform aimed at improving operational efficiency and profitability [3] - CYIOS Corporation operates across multiple industries, including medical supplies, technology, and fintech, with a focus on sustainable profitability through its subsidiary Noir Medical Supplies [4]

Market Outlook - Top Glove 预计在 2026 财年扩大美国销售额 [1] - 手套制造商面临来自中国竞争对手日益激烈的竞争 [1]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of fiduciary duty breaches by the board of directors during the class period from February 16, 2023, to February 12, 2025 [1][6]. Company Overview - West Pharmaceutical Services, Inc. is a medical supplies company based in Exton, Pennsylvania, serving as a key supplier to the pharmaceutical, biotechnology, and generic drug industries [6]. Allegations and Issues - The class action complaint alleges that West failed to disclose significant destocking issues in its high-margin High-Value Products portfolio, contrary to claims of strong visibility into customer demand [6]. - It is claimed that West's SmartDose device, intended as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [6]. - The complaint also highlights that margin pressures could lead to costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [6]. - Positive statements made by the company regarding its business and prospects were allegedly materially false or misleading [6]. Disclosure and Impact - The truth about the alleged fraud was revealed through a series of disclosures, culminating on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025 [6]. - The disappointing guidance was attributed to contract manufacturing headwinds, including the loss of two major continuous glucose monitoring customers transitioning to in-house manufacturing [6]. - Following this news, West's stock experienced a significant decline, dropping $123.17 per share, or 38%, to close at $199.11 on February 13, 2025 [6].

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: Owens & Minor has struck a deal to sell a unit that provides products and services to healthcare providers, the company said Tuesday.  Platinum Equity is paying $375 million for the business. The Owens & Minor unit will join healthcare companies including ASP Global, LifeScan and NDC in the investment firm’s portfolio.  The sale, which is scheduled to ...

Company Insights - Gerresheimer is a German medical supplies company specializing in packaging products made from specialty glass and plastics, primarily for medication and drug delivery devices [3] - The company was the world's leading manufacturer of vaccine glass vials during the pandemic, with production volumes reaching around 3.5 billion in 2021 [3] - Gerresheimer is currently known for producing injection pens used in the weight loss drug Ozempic, although its plastics and devices division has underperformed recently [4] Financial Performance - Gerresheimer's stock has fallen by 70% since its pandemic-era peak, with recent challenges including a flooded US plant during Hurricane Helene in September 2024 [4] - The company’s share price has dropped from nearly EUR 90 offered by private equity firms KKR and Warburg Pincus to just EUR 37 today [5] - The CFO's resignation and an investigation by Germany's financial regulator BaFin into alleged accounting violations have contributed to the decline in share price [7] Market Opportunities - An upcoming investor day on October 15, 2025, may present a potential catalyst for Gerresheimer, with speculation about the sale of its moulded glass business [8] - If the sale occurs, it could initiate a turnaround narrative for the company, with a potential 30% upside in stock price [10] i-80 Gold Corp. Insights - i-80 Gold Corp. has been one of the worst-performing gold mining companies over the past five years, with its share price falling from CAD 4 to CAD 1 despite a doubling of gold prices [11] - The appointment of a new CEO, an accountant, marks a significant shift in management strategy, with hopes of building a mining operation capable of producing 600,000 ounces of gold annually by 2032 [13][14] - The current market cap of i-80 Gold Corp. is CAD 1 billion, which is significantly lower than typical market caps for similar-sized gold mining operations [14][15] Novo Nordisk Insights - Novo Nordisk operates in a duopoly in the weight loss drug market alongside Eli Lilly, with its stock price dropping from DKK 1,000 to under DKK 400 in the past year [16][17] - Recent setbacks include a drug trial that reported 23% weight loss, slightly below the projected 25%, leading to a CEO departure [19] - Despite challenges, the global market for weight loss drugs is expected to remain dominated by branded products, with Novo Nordisk potentially regaining a strong market position [21] - Novo Nordisk trades at about one-third the multiples of Eli Lilly, suggesting a potential upside of 50-100% as market concerns fade [22]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Zynex, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1] Company Overview - Zynex, Inc. is facing scrutiny for allegedly inflating its stock price through false and misleading statements regarding its financial performance and operational practices [6] - The company reportedly engaged in a systemic "oversupplying scheme," shipping excessive quantities of supplies and billing insurers for inflated amounts [6] Financial Impact - The misconduct was revealed on March 11, 2025, when Zynex announced a significant revenue shortfall attributed to slower payments from insurers, particularly Tricare, which accounts for 20-25% of its annual revenue [6] - Following the announcement, Zynex's stock price dropped by $3.59 per share, or 51.3%, closing at $3.41 per share, resulting in a substantial loss of shareholder value [6]

Core Insights - Cardinal Health has opened a new distribution center in Fort Worth, Texas, dedicated to its at-Home Solutions business, which serves over 6 million people annually in the U.S. [1] - The Fort Worth facility is the third distribution center built from the ground up in three years, with a size of 340,000 square feet, capable of shipping approximately 10,000 packages daily [2] - The company has expanded its distribution network by over 750,000 square feet in three years, incorporating advanced robotics and automation technology [3] Investment and Expansion - Cardinal Health is committed to investing in its supply chain, emphasizing the necessity of enhancing distribution capabilities to meet customer needs [4] - Plans for further expansion include breaking ground on a new distribution center in Sacramento, California, and retrofitting an existing facility in Ontario, California, with advanced technology [5][6] - The Sacramento facility is expected to be operational by Summer 2027, aimed at improving delivery efficiency on the West Coast [6]

Core Insights - Dimora Medical has launched the Dimora PHMB Skin and Wound Cleanser to address the challenges of chronic wound care, particularly for aging populations [1][15] - The cleanser effectively tackles biofilms, which complicate over 78% of chronic wounds, by breaking them down and killing 99.99% of bacteria within minutes [1][4][8] Product Features - The main ingredient, Polyhexamethylene Biguanide (PHMB), has demonstrated the ability to remove 99.49% of biofilm within three minutes and 99.99% after seven minutes [5] - The cleanser provides rapid antimicrobial action, killing 99.99% of bacteria in just two minutes for infected wounds and in one minute for non-infected wounds [8][9] - The product maintains its antimicrobial strength over time, achieving a 99.99% reduction in bacteria even after being opened for 28 days [12] Benefits for Caregivers - The cleanser simplifies the wound care process, allowing caregivers to clean and protect wounds quickly without multiple steps [9][15] - It reduces the risk of infection and complications, providing families with greater confidence in managing chronic wounds at home [6][16] - Dimora Medical aims to make home care easier and less stressful for families, positioning itself as a trusted expert in wound care [15][16]

Public Health Emergency - Botswana's President declared a public health emergency [1] - A 5 billion Pula (approximately $348 million) response plan has been established [1] Economic Impact - A prolonged downturn in diamond sales is cited as the cause [1] - The downturn has led to a shortage of funds for medical supplies [1]